Artificial intelligence is increasingly integrated within biomedical fields, exemplified by models predicting glioma genetic markers with high accuracy and deep learning frameworks advancing gastric and sinus surgery image analyses. However, concerns arise as FDA-deployed AI tools like Elsa generate fabricated studies, casting doubt on data fidelity and regulatory reliance on AI outputs. These developments highlight a dual-edged trend wherein AI accelerates innovation yet necessitates stringent validation to prevent misinformation and safeguard public health.